Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual Meeting and Exposition
10 déc. 2022 18h30 HE
|
Agios Pharmaceuticals, Inc.
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependent α- or β-Thalassemia, Respectively – – Agios to...
Agios Appoints Tsveta Milanova as Chief Commercial Officer
06 déc. 2022 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios to Participate in December Investor Conference
30 nov. 2022 08h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
10 nov. 2022 16h01 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined...
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition
03 nov. 2022 09h00 HE
|
Agios Pharmaceuticals, Inc.
– Long-term Data for PYRUKYND® (mitapivat) in Adults with Pyruvate Kinase (PK) Deficiency and Adults with Thalassemia Demonstrate Sustained Improvement in Hemoglobin, Markers of Hemolysis and Other...
Agios Reports Business Highlights and Third Quarter 2022 Financial Results
03 nov. 2022 07h00 HE
|
Agios Pharmaceuticals, Inc.
– U.S. PYRUKYND® (mitapivat) Launch Provides Capability Building Platform to Support Expected Future Product Growth and Expansion; Net Revenue of $3.5 Million in Q3 – – Received Positive CHMP...
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
27 oct. 2022 16h01 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and TORONTO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically...
Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022
20 oct. 2022 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined...
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
26 sept. 2022 19h13 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined...
Agios Appoints Cecilia Jones as Chief Financial Officer
19 sept. 2022 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined...